STOCK TITAN
  1. Home
  2. Sec-filings
  3. BTAI
  4. [8-K] BioXcel Therapeutics, Inc. Reports Material Event

BioXcel attaches BXCL501 commercial opportunity deck; SERENITY Phase 3 results pending

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

BioXcel Therapeutics disclosed a corporate presentation on its website describing the commercial opportunity for BXCL501 in connection with upcoming SERENITY At-Home Phase 3 study results. The filing states the presentation is attached as Exhibit 99.1 and that the exhibit contains forward-looking statements, which are based on current expectations and subject to limitations disclosed in the exhibit and the company’s other SEC filings.

The report does not present clinical data, financial results, or material transactions; it serves to communicate the company’s commercial case for BXCL501 and to make related forward-looking commentary available to investors.

Positive

  • Company provided a corporate presentation to communicate BXCL501's commercial opportunity to investors
  • Exhibit 99.1 was attached, increasing transparency by making the presentation part of the public record

Negative

  • No clinical study results or data were disclosed
  • Presentation contains forward-looking statements subject to limitations and may not reflect actual future results
  • No financial statements, material transactions, or metrics were included that would change an investor’s valuation assessment

Insights

TL;DR: Routine investor communication; no new clinical or financial results disclosed, contains forward-looking statements.

The 8-K reports that BioXcel posted a corporate presentation outlining BXCL501's commercial opportunity tied to forthcoming SERENITY At-Home Phase 3 results and attached that presentation as Exhibit 99.1. From a securities perspective, this is a disclosure-oriented filing intended to provide investors with the company’s current commercial rationale and expectations. The filing explicitly warns that the exhibit includes forward-looking statements and references limitations contained in other SEC reports. There are no financial statements, metrics, or material transactions in this report to materially change valuation models.

TL;DR: Clinical results are not reported here; the presentation appears preparatory for imminent SERENITY At-Home Phase 3 readouts.

The document confirms a presentation was posted to highlight BXCL501's commercial opportunity in the context of upcoming Phase 3 study results but does not include trial data, endpoints, or timing details. As such, the filing signals preparatory investor outreach rather than clinical milestones being achieved or disclosed. The explicit forward-looking statement notice indicates the company is framing expectations rather than reporting outcomes.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
false 0001720893 0001720893 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

  

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 11, 2025

 

 

BioXcel Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-38410   82-1386754
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

555 Long Wharf Drive

New Haven, CT 06511

(Address of principal executive offices, including Zip Code)

 

(475) 238-6837

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which registered

Common Stock, par value $0.001   BTAI   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨

 

 

 

 

 

Item 8.01. Other Events.

 

On August 11, 2025, BioXcel Therapeutics, Inc. (the “Company”) posted a presentation on its website regarding BXCL501’s commercial opportunity related to the upcoming study results from the SERENITY At-Home Phase 3 trial, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Forward-Looking Statements

 

Exhibit 99.1 attached hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number		   Exhibit Description
99.1   Corporate Presentation dated August 11, 2025.
104   Cover Page Interactive Data File (embedded within Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 11, 2025 BIOXCEL THERAPEUTICS, INC.
     
    /s/ Richard Steinhart
  By: Richard Steinhart
  Title: Chief Financial Officer

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What did BioXcel (BTAI) disclose in this Form 8-K?

The company posted a corporate presentation on its website about BXCL501's commercial opportunity related to upcoming SERENITY At-Home Phase 3 study results and attached that presentation as Exhibit 99.1.

Did the 8-K include SERENITY Phase 3 study results?

No. The filing references upcoming study results but does not disclose any clinical data or trial outcomes.

What exhibits were filed with the 8-K?

The filing lists Exhibit 99.1: Corporate Presentation and Exhibit 104: Cover Page Interactive Data File.

Are the statements in the presentation factual or forward-looking?

The filing states that Exhibit 99.1 contains forward-looking statements based on current expectations and subject to the limitations described in the exhibit and other SEC reports.

Does the filing include financial information or major transactions?

No. The 8-K does not present financial statements, financial metrics, or material transactions.